On the 27th, Boehringer Ingelheim announced at the Chinese headquarters in Shanghai that the second-generation EGFR-targeted drug, afatinib, for lung cancer treatment has been approved in China, after the domestic patients obtained the drug by overseas purchasing, sometimes It is called 2992 by the patient. Lung cancer is one of the most common malignant tumors in China. About 600,000 new lung cancer patients are added each year, which is the leading cause of cancer death in China.
Currently, lung cancer can be roughly classified into non-small cell lung cancer and small cell lung cancer, and non-small cell lung cancer accounts for 80-85% of all lung cancers. For patients with early stage lung cancer, comprehensive treatment methods including surgery are often used. For patients with advanced non-small cell lung cancer, traditionally, they mainly rely on radiotherapy and chemotherapy. Currently, some patients directly take targeted drugs or in radiotherapy and chemotherapy. Try to take a targeted drug after it is invalid.
Common types of lung cancer gene mutations include EGFR, ALK, KRAS, etc. The distribution of gene mutation types varies among different ethnic groups. The EGFR mutation in lung cancer patients in Europe and America is about 10-15%, and up to 50% in non-small cell lung cancer patients in China.
This domestically approved afatinib is the second generation of EGFR TKI (tyrosine kinase inhibitor). Unlike the first-generation reversible EGFR TKI, afatinib binds irreversibly to EGFR, thereby shutting down the cancer cell signaling pathway and inhibiting tumor growth. Clinical studies have shown that afatinib is the first and only TKI7-8 to prolong the survival of the most common EGFR-mutant type of lung cancer patients compared to the best chemotherapy regimen. Compared with the first generation of EGFR TKI gefitinib (Iressa), afatinib reduced the risk of lung cancer progression and the risk of treatment failure by 26%, and the number of progression-free patients who received afatinib after two years of treatment was Twice the treatment with gefitinib.
Located at the Boehringer Ingelheim CMO Base Building in Zhangjiang Hi-Tech Park, Shanghai
Arterial Blood Gas Collection Syringe
Arterial Blood Gas Collection Syringe,Arterial Blood Syringe,Syringe,arterial blood gas syringe,disposable syringe
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com